Cerebras is listed on the Nasdaq stock exchange, receiving research coverage from Morgan Stanley and aggregated ratings via MarketBeat.
3 reports, 3 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cerebras is listed on the Nasdaq stock exchange, receiving research coverage from Morgan Stanley and aggregated ratings via MarketBeat.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cerebras filed SEC disclosures and received analyst ratings from Morgan Stanley.1 source
Cerebras listing on Nasdaq is accompanied by research coverage and consensus ratings.1 source
Keep exploring
The entities involved
-
Cerebras
business
- A composite article detailing several distinct corporate news items from July 1, 2026, including a CrowdStrike/Cerebras deal, an AMD/Cerbras partnership, Intel earnings, and Kinder Morgan profits.
- The article notes that both AMD and Cerebras are operating in the high-demand AI compute market, and Andrew Feldman is the CEO of Cerebras.
-
Nasdaq
American fully electronic stock exchange
Related events
- OpenAI announced a multi-year partnership with Cerebras, which is listed on the Nasdaq stock exchange and benefits from potential Trump-era tariffs.
- BioHarvest Sciences Inc is listed on the Nasdaq stock exchange and is receiving analyst ratings and targets from MarketBeat.
- BayFirst Financial Corp is listed on the electronic stock exchange and analysts are using it for consensus ratings.
- MarketBeat provides ratings for listed companies.
- ProKidney and Cartesian Therapeutics were listed on the Nasdaq stock exchange and received ratings from MarketBeat.